Weight-Loss Jabs and Eye Problems: What the Headlines Leave Out

Mounjaro, Ozempic, Wegovy — you've seen the headlines, and millions of people are now searching about vision loss and eye damage. I understand why you're looking this up. These headlines are generating real fear and, in most cases, real confusion — not because the risk doesn't exist (it does, and I want to be honest with you about that), but because the way it's been reported leaves out the most important part of the picture.

I'm Mr Dilraj Sahota, a consultant ophthalmologist in the West Midlands, with training from Oxford University and Moorfields Eye Hospital in London. Below, I'll separate three issues that are constantly bundled together, and explain how the risk is actually measured — which changes how you should read those headlines.

There are three separate issues, with different mechanisms and different levels of urgency:

1. Temporary blurry vision — usually settles, usually benign, quite common.
2. Early worsening of diabetic retinopathy — relevant if you already have diabetic eye disease.
3. NAION — a rare but serious eye condition. This is the one behind all the headlines.

Treating them all as one is where the confusion starts.

Thousands of people search "Mounjaro blurry vision" within weeks of starting the medication, assuming it's damaging their eyes. In the majority of cases, it is not.

GLP-1 medications work wonderfully to lower blood sugar, and they often do so very quickly. When blood glucose drops rapidly, fluid shifts within the natural lens of the eye. This temporarily changes the lens shape — and therefore your optical prescription. Glasses that gave you clear vision last month suddenly don't, and your vision blurs.

But the lens itself is not damaged. As your blood sugars normalise and stabilise, your prescription returns to normal and the blurring usually settles.

What to do: if you're in the first 4 to 6 weeks of starting a new GLP-1 medication and your vision has blurred, don't rush to update your prescription yet. But if the blurring persists beyond six weeks, or you get sudden loss of vision or blurring in one eye, see your optometrist immediately. If it simply hasn't settled after six weeks, you may still need to update your glasses. This is the most common explanation for blurry vision on these medications.

This one is different — it applies to people who have diabetic eye disease. If you have diabetes and you're being started on a GLP-1 medication, this is the issue to understand properly.

The key findings come from a major clinical trial called SUSTAIN-6. In that trial, diabetic patients on semaglutide had a 76% higher rate of diabetic eye complications compared with those on placebo — things like bleeding at the back of the eye, or needing laser treatment to stabilise vision.

76% sounds alarming. Here's the vital context the coverage misses: this is the same early-worsening effect we've seen for decades when diabetic patients start on insulin. When blood sugar improves rapidly — whether from insulin, from a GLP-1, or from any other effective diabetic medication — the already-damaged microvasculature at the back of the eye temporarily worsens, before the long-term benefits of lower blood sugar take hold. It's the speed of the improvement that triggers it, not a toxic effect of the drug itself.

I had a patient in clinic — diabetic maculopathy, high HbA1c, on treatment — whose doctor had rightly suggested she start a GLP-1 medication. She'd read the headlines and asked me directly: "Will this damage my eyes?" That question deserved a thorough, evidence-based answer, not vague reassurance — and she's part of the reason I made this.

If you're diabetic and starting a GLP-1: do not stop, do not panic — but do make sure you're attending your NHS diabetic retinopathy screening, and tell your team you're starting the medication so the review interval can be adjusted. The drug is not inherently damaging to the retina; the vigilance is about managing the transition until blood sugar stabilises.

The condition behind most of the alarming headlines is NAION — non-arteritic anterior ischaemic optic neuropathy. Eye specialists sometimes call it an "eye stroke," though that term isn't quite precise.

Who is at risk: the "two-hit" hypothesis

The optic nerve usually takes two hits to be damaged to the point where vision is affected.

• Hit one is anatomical. Some people are born with an optic nerve disc that is smaller, tighter and more crowded — the same number of nerve fibres passing through a tighter space.
• Hit two is vascular. Blood flow to that already-crowded disc becomes compromised, worsened by systemic risk factors such as high blood pressure, obesity, sleep apnoea or poorly controlled diabetes.

When a tight optic disc meets compromised blood flow, the nerve swells — which compromises blood flow further — and the nerve becomes damaged. That's NAION.

What NAION actually does to vision

The experience is a sudden, painless loss of vision in one eye, usually described as a shadow, often noticed on waking, and typically affecting the lower (inferior) part of your vision.

Importantly, total blindness is very rare with NAION. In fact, if I see a patient with total loss of vision in one eye, I'm thinking about a different condition — giant cell arteritis — not NAION. The realistic picture is more nuanced: around half of patients retain useful central vision, and around 40% get some improvement over time. The part that doesn't usually recover is the visual field loss — if you lost the inferior part of your vision, that tends not to come back. NAION is serious and not trivial, but "Ozempic causes blindness" doesn't give the full picture.

⚠️ Same-day eye casualty. If you're on a GLP-1 medication and develop sudden blurry vision in one eye — like a shadow, a curtain, or a grey cloud — go to eye casualty the same day. Do not wait for a routine appointment.

In February 2026, the UK medicines regulator (the MHRA) updated the safety information for semaglutide — that's Wegovy, Ozempic and Rybelsus. Following a Europe-wide review by the European Medicines Agency, their conclusion was that NAION is a very rare side effect associated with semaglutide.

In regulatory language, "very rare" has a specific meaning: it can affect up to 1 in 10,000 people taking the medication. The MHRA did not say most people get vision problems, and did not say stop the medication. They said this is a very rare side effect, and that if you experience sudden blurry vision you must seek urgent ophthalmic assessment. This was the regulator's conclusion after reviewing multiple large epidemiological studies — not just odd case reports — and it's considerably more measured than the headlines.

"Doubles the risk" — doubled from what?

Many articles say semaglutide doubles the risk. The question to ask is always: doubled from what? A relative risk tells you the ratio; it doesn't tell you the absolute numbers.

Here are the concrete figures. NAION affects around 10 in 100,000 people per year in the general population. In people with type 2 diabetes the background level is already higher — varying between roughly 11 and 80 per 100,000 per year. The best available meta-analysis (a high level of scientific evidence) found semaglutide is associated with a doubling of NAION risk — and the MHRA and European regulators translate that doubling into one additional case of NAION per 10,000 patients treated. Whenever you read that a medical risk has "doubled," always ask what it doubled from.

This distinction matters. Mounjaro contains tirzepatide. Wegovy and Ozempic contain semaglutide. They're not identical — think of them as cousins from the same drug family.

The overwhelming majority of the scary headlines are based on semaglutide data, yet are frequently reported as though they apply to all weight-loss medications, including Mounjaro. A major pharmacovigilance study published in the British Journal of Ophthalmology in 2026, analysing millions of adverse-event reports globally, found a signal for semaglutide — but the current evidence does not show the same signal for tirzepatide.

That doesn't mean Mounjaro carries zero risk — we don't have the same volume of data, and research is ongoing. But current evidence has not demonstrated the same increased NAION association with tirzepatide as with semaglutide. That's particularly relevant for UK patients, where Mounjaro prescribing is increasing. It's reassuring for Mounjaro users — but not a green light to ignore vision problems.

• Four factors typically show an increased risk of NAION in the evidence:

  • Older age, particularly over 50
  • Male sex
  • Systemic risk factors — high blood pressure, uncontrolled diabetes, obesity, sleep apnoea
  • A small, crowded, tight optic disc — the "first hit" described above

  If you have several of these factors and you're being started on semaglutide specifically, it makes sense to ask your prescriber whether a baseline eye examination would be sensible. You won't get a clear-cut protocol at this early stage of these new medications — that clarity is still being established — but you're entitled to ask.

These medications, when they work, prevent heart attacks and strokes and extend lives that would otherwise be shortened by cardiovascular disease or long-term high blood sugar. And the patients most at risk of the eye complications discussed here are often the very patients who stand to gain the most from treatment.

The risk is real. It's not zero — but it is small. The decision about whether to take these medications is one for you and your doctor to make together, with accurate information rather than a headline.

• There are three distinct issues, not one: temporary blurry vision, early worsening of diabetic retinopathy, and NAION
• Early blurry vision is usually a temporary prescription shift as blood sugar falls — don't rush to change glasses in the first 4–6 weeks
• If you're diabetic, don't stop or panic — but keep attending NHS retinopathy screening and tell your team you've started
• NAION is very rare (up to 1 in 10,000 for semaglutide) — the regulators translate the "doubling" into about one extra case per 10,000 treated
• Mounjaro (tirzepatide) does not currently show the same NAION signal as semaglutide, though data is still emerging
• Sudden painless vision loss or a shadow/curtain in one eye = same-day eye casualty

Does Mounjaro cause blindness?

The headlines overstate this. The condition behind them, NAION, is very rare, and total blindness from it is itself rare — around half of patients retain useful central vision. Importantly, current evidence has not shown the same NAION signal for Mounjaro (tirzepatide) as for semaglutide, though research is ongoing.

Why is my vision blurry after starting a weight-loss jab?

In most cases it's a temporary shift in your glasses prescription. As these medications rapidly lower blood sugar, fluid moves within the lens and changes its shape. The lens isn't damaged, and vision usually settles as blood sugar stabilises. Don't update your prescription in the first 4–6 weeks, but see your optometrist if it persists beyond six weeks or is sudden and one-sided.

Is Ozempic or Mounjaro safer for the eyes?

Most of the concerning data relates to semaglutide (Ozempic, Wegovy). A 2026 pharmacovigilance study found a signal for semaglutide but not for tirzepatide (Mounjaro). That's reassuring for Mounjaro users, but not a reason to ignore any vision changes, and it doesn't mean the risk is zero.

Should I stop my weight-loss injection if I'm worried about my eyes?

Do not stop or panic based on headlines — these medications have major cardiovascular and metabolic benefits. If you have diabetes, keep attending your NHS retinopathy screening and tell your team you've started. If you have several NAION risk factors and are starting semaglutide, ask your prescriber about a baseline eye check. Any decision to start or stop is one to make with your doctor.

What eye symptoms on a weight-loss jab are an emergency?

Sudden, painless loss of vision in one eye, or a shadow, curtain or grey cloud across your vision. Go to eye casualty the same day rather than waiting for a routine appointment.

If you're taking — or considering — a GLP-1 medication and you'd like your eyes assessed, or you have diabetic eye disease and want a specialist review, Mr Dilraj Sahota offers consultant-led ophthalmology and medical retina care in Edgbaston, serving Birmingham and the wider West Midlands. Book a consultation, or arrange a free 10-minute video call to talk it through. If you have diabetes and want to understand how diabetic retinopathy affects your eyes, read my guide to diabetic retinopathy symptoms and when to act.

This article is for general information and patient education. It is not a substitute for a personal consultation, diagnosis or treatment from a qualified clinician, and it is not advice to start or stop any medication. Never change a prescribed medication without speaking to your doctor. If you have diabetes, please continue to attend your NHS diabetic eye screening, and seek urgent care for any sudden change in vision.

Last updated: July 2026.